Stock Track | GENSCRIPT BIO Plummets 5.54% Intraday on Profit-Taking After ASCO Rally and Sector Weakness

Stock Track05-28

GENSCRIPT BIO's stock price plummeted 5.54% during intraday trading on Thursday, marking a significant reversal from its previous session's gains.

The decline appears to be driven by profit-taking activity following a rally in the prior session, which was catalyzed by positive research results from its associate company Legend Biotech at the ASCO annual meeting. Additionally, concerns over institutional selling have emerged, with Hong Kong Stock Connect channels experiencing consecutive days of significant net outflows prior to this session.

Broad weakness across the Life Sciences Tools & Services sector further pressured sentiment, with multiple major players in the space also trading lower during the session, contributing to the overall downward movement in GENSCRIPT BIO's share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment